@article {Kifer2021.04.10.21255252, author = {Domagoj Kifer and Helena Deri{\v s} and Ana Cindri{\'c} and Tea Petrovi{\'c} and Ana Cvetko and Irena Trbojevi{\'c}-Akma{\v c}i{\'c} and Louise Newson and Tim Spector and Cristina Menni and Gordan Lauc}, title = {Immunoglobulin G glycome composition in transition from pre-menopause to menopause}, elocation-id = {2021.04.10.21255252}, year = {2021}, doi = {10.1101/2021.04.10.21255252}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Glycosylation of immunoglobulin G (IgG) is an important regulator of the immune system and its changes are believed to be a significant contributor to inflammaging. Gonadal hormones affect IgG glycome composition, suggesting that alterations in IgG glycosylation might be one of the molecular mechanisms behind increased disease risk in perimenopause.Methods IgG was isolated from 5,354 plasma samples collected from 1,940 females and 113 males at multiple time points. IgG glycans were released, labelled with a fluorescent dye and analysed by ultra-high-performance liquid chromatography. Mixed modelling was used to determine average levels of individual IgG glycans in pre-menopausal women, menopausal women, and men.Findings Large and statistically significant differences in IgG glycome composition were observed, mainly reflecting decreased galactosylation and sialylation of glycans in menopausal women. During perimenopause women had a significant higher rate of increase in agalactosylated structures (0.051/yr; 95\%CI = 0.043 - 0.059, p\<0.001), and decrease in digalactosylated (-0.043/yr; 95\%CI = -0.050 {\textendash} -0.037, p\<0.001), and monosialylated glycans (- 0.029/yr; 95\%CI = -0.034 {\textendash} -0.024, p\<0.001), compared to premenopausal women.Interpretation Proinflammatory IgG glycome and the resulting decrease in the ability of IgG to suppress low-grade chronic inflammation may be an important molecular mechanism mediating the increased health risk in perimenopause. IgG glycome changes considerably during perimenopause and may aid the diagnosis of perimenopause.Funding Croatian National Centre of Excellence in Personalised Healthcare, ESI Funds grant for the Centre of Competences in Molecular Diagnostics, the Wellcome Trust and the Medical Research Council (MRC)/British Heart Foundation (BHF).Competing Interest StatementA patent covering all the main aspects of the use of IgG glycome as a predictor of menopause and perimenopause has been filed by Genos Ltd (application number: P20210509A). The application is currently pending. D.K., C.M., and G.L. are named as co-inventors on the patent application. G.L. is the founder and owner of Genos Ltd, a biotech company specialising in high-throughput glycomics that also has several patents in the field. H.D., A.Ci. T.P., and I.T.-A. are employees of Genos Ltd. The remaining authors declare no competing interests.Clinical TrialThe TwinsUK study was approved by NRES Committee London - Westminster, and all twins provided informed written consentFunding StatementThis study has been supported by the Croatian National Centre of Excellence in Personalised Healthcare (Contract no. KK.01.1.1.01.0010), ESI Funds grant for the Centre of Competences in Molecular Diagnostics and the Human Glycome Project. Equipment and products from Waters and New England Biolabs were used for this research. The Department of Twin Research receives support from grants from the Wellcome Trust (212904/Z/18/Z) and the Medical Research Council (MRC)/British Heart Foundation (BHF) Ancestry and Biological Informative Markers for Stratification of Hypertension (AIM-HY; MR/M016560/1), European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd., the NIHR Clinical Research Facility and Biomedical Research Centre (based at Guy{\textquoteright}s and St Thomas{\textquoteright} NHS Foundation Trust in partnership with King{\textquoteright}s College London). C.M. is funded by the Chronic Disease Research Foundation and by the MRC AIM-HY project grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The TwinsUK study was approved by NRES Committee London-Westminster, and all twins provided informed written consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon a reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/04/17/2021.04.10.21255252}, eprint = {https://www.medrxiv.org/content/early/2021/04/17/2021.04.10.21255252.full.pdf}, journal = {medRxiv} }